Abstract:Abstract Background Thiopurine therapy is associated with an increased risk of serious adverse events in patients with Inflammatory Bowel Disease (IBD). Thiopurine S-methyltransferase (TPMT) is the enzyme responsible for metabolism, and its determination helps identify patients at risk of toxicity. This study aims to explore the level of correspondence between the TPMT genotype and enzymatic activity (phenotype) with the objective of preventing adverse events prior to the commencement of thiopurine therapy. Methods Consecutive patients with IBD, Crohn’s Disease (CD) or Ulcerative Colitis (UC), were included. Genotype was conducted for the most prevalent TPMT variants (TPMT*2, TPMT*3B, TPMT*3C), TPMT enzymatic activity assessment, and quantification of 6-thioguanine nucleotide (6-TGN) levels. Adverse effects were documented, along with the administration of biologics, mesalazine, ACE inhibitors or allopurinol. The primary objective was to evaluate the concordance between TPMT genotype and phenotype. Secondary objectives included determining the prevalence of genotype and phenotype within our patient cohort, 6-TGN serum levels, the prevalence of adverse events and identifying potential pharmacological inducers of the phenotype. Results A total of 218 patients were included (131 with CD and 81 with UC). Thirteen patients did not initiate thiopurines, and 34.63% (71/205) had discontinued treatment. The most observed adverse events were myelotoxicity (15.12%), gastrointestinal toxicity (12.20%), and hepatic toxicity (5.37%). TPMT activity exhibited a trimodal distribution, with 87.61% (191/218) having normal activity, 11.47% having intermediate activity, and 1% having low activity. Genotypically, 90.83% (198/218) had a wild-type genotype, 8.72% (18/218) had a heterozygous genotype, and 0.5% (1/218) had a homozygous genotype. The concordance index between phenotype and genotype was calculated at 0.57. Significantly, myelotoxicity was associated with the presence of genotypic variants (p=0.004). 6-TGN levels did not correlate with TPMT activity and concurrent medications did not affect TPMT activity . Conclusion The proactive assessment of TPMT (phenotype or genotype) before initiating thiopurine therapy effectively mitigates the occurrence of myelotoxicity in IBD patients. Importantly, the level of concordance between TPMT activity and genotype is moderate, with genotyping serving as the more reliable approach for preselecting patients susceptible to myelotoxic reactions.

Role of Thiopurine S-Methyltransferase Detection in the Treatment of Inflammatory Bowel Disease

Correlation between Thiopurine S-methyltransferase and Thiopurines Toxicity in Patients with Inflammatory Bowel Disease

Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine.

Evaluation of thiopurine methyltransferase genotyping and enzyme activity detection in treatment of patients with inflammatory bowel disease

Thiopurine Methyltransferase Gene Polymorphisms in Chinese Patients with Inflammatory Bowel Disease

Prospective Evaluation of Pharmacogenomics and Metabolite Measurements Upon Azathioprine Therapy in Inflammatory Bowel Disease

P798 Study of the concordance between the enzymatic activity of Thiopurine S-methyltransferase and polymorphisms in the TPMT gene in patients with Inflammatory Bowel Disease

Thiopurine S-methyltransferase Polymorphisms and Thiopurine Toxicity in Treatment of Inflammatory Bowel Disease.

Role of TPMT Genetic Polymorphism in the Individualized Treatment of Thiopurine Drug

The Role of Pharmacogenetics in the Therapeutic Response to Thiopurines in the Treatment of Inflammatory Bowel Disease: A Systematic Review

Association Between Thiopurine S-Methyltransferase Polymorphisms And Thiopurine-Induced Adverse Drug Reactions In Patients With Inflammatory Bowel Disease: A Meta-Analysis

Should Thiopurine Methyltransferase Genotypes and Phenotypes Be Measured Before Thiopurine Therapy in Patients with Inflammatory Bowel Disease?

Significance of genetic polymorphism of the thiopurine S-methyltransferase for individualizing 6-mercaptopurine chemotherapy

Significance of TPMT activity and TGNs level detection for individualizing 6-mercaptopurine chemotherapy]

Hypoxanthine Guanine Phosphoribosyltransferase Activity is Related to 6-Thioguanine Nucleotide Concentrations and Thiopurine-Induced Leukopenia in the Treatment of Inflammatory Bowel Disease

Association Between Thiopurine S-Methyltransferase Polymorphisms And Azathioprine-Induced Adverse Drug Reactions In Patients With Autoimmune Diseases: A Meta-Analysis

Correlation Between TPMT Polymorphisms and Azathioprine Toxicity in the Treatment of Inflammatory Bowel Disease: A Meta Analysis

Study on the Relationship Between Genetic Polymorphism of TPMT and ITPA with Adverse Drug Reactions in 6-Mercaptopurine Treatment

[Association Between Metabolic Enzyme Genotype of Azathioprine and Drug Tolerance in Patients with Rheumatic Diseases].

Relationship Between MDR1C1236T Polymorphism and Active Metabolite of 6-Thioguanine Nucleotide in Patients with the Inflammatory Bowel Disease

Inosine Triphosphate Pyrophosphatase and NUDT15 Are Good Predictors of Clinical Outcomes in Thiopurine-Treated Chinese Patients with Inflammatory Bowel Disease.